Co-Diagnostics Inc. (NASDAQ: CODX) announced it has advanced its PCR assay development strategy for the Bundibugyo virus currently causing an Ebola outbreak in the Democratic Republic of the Congo and Uganda, working with CoSara Diagnostics Pvt. Ltd., its Indian joint venture with Ambalal Sarabhai Enterprises Limited.

The joint development strategy aims to address international deployment requirements if the current outbreak continues or expands globally. CoSara's regional manufacturing and operational capabilities may support rapid deployment initiatives in certain international markets, subject to regulatory requirements.

The development program includes evaluation of both Bundibugyo virus-specific and pan-Ebola assay configurations designed to detect multiple ebolavirus species. The company is also evaluating workflow configurations for point-of-care and decentralized testing environments for the Co-Dx PCR platform.

On May 25, the World Health Organization reported that the Ebola outbreak caused by Bundibugyo virus, which WHO declared a public health emergency of international concern on May 17, 2026, has resulted in more than 900 suspected cases and 220 suspected deaths. WHO stated the epidemic is currently outpacing response operations.

"Being able to work with our CoSara colleagues to provide accurate, reliable PCR diagnostics on a global scale in response to emerging healthcare crises is one of our most valuable strategic attributes," said Dwight Egan, Chief Executive Officer of Co-Diagnostics.

The Co-Dx PCR platform, including the PCR Home, PCR Pro, mobile app, and associated tests, remains subject to review by the FDA and other regulatory bodies and is not yet available for sale.